Sarah Smith

Sarah Smith

Expertise: ESG Investing, Electric Vehicle Stocks, Short Squeeze Stocks

Education: BA, Government and Gender, Sexuality and Women’s Studies, The College of William & Mary

Awards & Accomplishments: Top 5% of stock pickers on TipRanks

About Sarah:
Sarah Smith is an experienced editor and writer who works to help retail investors make sense of what’s happening every day on Wall Street, and she’s particularly interested in ESG investing, EV stocks, and the rise of speculative trading activity like short squeezes. She has also written for Kiplinger.com, Smithsonian, and Washington City Paper. Sarah is currently working to become a Chartered Financial Analyst (CFA) and has already earned bachelor’s degrees in Government and Gender, Sexuality and Women’s Studies from the College of William and Mary. Her work for InvestorPlace.com focuses on helping investors understand the causes and impacts of daily stock and crypto market movements, and how a disruption in who invests – and how they invest – transforms the market. Sarah is recognized among the top 5% of stock pickers on TipRanks and has an average return of 50%. She lives in Arlington, Virginia.

Connect with Sarah on LinkedIn.

Recent Articles

OGEN Stock: Why Oragenics Is Soaring 25%

Oragenics is planning to launch clinical trials of its coronavirus vaccine in early 2021. OGEN stock is soaring on the news.

LONE Stock: Why Lonestar Is Soaring 100%

Lonestar just received approval to access its cash collateral during bankruptcy, and LONE stock is soaring on the news.

Trump Coronavirus News: Why the Market Is Sliding Today

The market is sliding on today on Trump coronavirus news following confirmation that President Donald Trump tested positive.

ENLV Stock: Why Enlivex Is Soaring 70% Today

Enlivex just announced that it will launch Phase 2 trials for a plasma-based coronavirus treatment, and ENLV stock is soaring in response.

CVAC Stock: CureVac Pops on Plans for Phase 2 Vaccine Trials

CureVac just announced it was launching Phase 2 trials in Peru and Panama for its coronavirus vaccine. CVAC stock is rallying in response.